FGF21 and obesity due to melanocortin 4 receptor deficiency: Multiple analogues or mimetics of FGF21 have been developed to solve this problem, some of which have completed phase I clinical trials with a noticeable improvement in obesity and T2D‐related symptoms in patients.51, 52